Haemonetics

Haemonetics Market capitalization

The The market capitalization of Haemonetics (HAE) as of Oct 20, 2026 is 2.68 B USD. In the previous year, The market capitalization was 2.68 B USD — a change of 0.00% (lower).

Market capitalization

2.68 BUSD

YoY

0.00%

Last updated:

In 2026, Haemonetics's market cap stood at 2.68 B USD, a 0.00% increase from the 2.68 B USD market cap in the previous year.

The Haemonetics Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2019
2.68 B USD
Jan 1, 2020
2.68 B USD
Jan 1, 2021
2.68 B USD
Jan 1, 2022
2.68 B USD
Jan 1, 2023
2.68 B USD
Jan 1, 2024
2.68 B USD
Jan 1, 2025
2.68 B USD
Jan 1, 2026
2.68 B USD
The Haemonetics Market capitalization history
YEARMarket capitalizationYoY
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD0.00%
2.68 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Haemonetics Stock analysis

What does Haemonetics do? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Haemonetics's Market Capitalization

Haemonetics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Haemonetics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Haemonetics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Haemonetics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Haemonetics stock

The market capitalization of Haemonetics is 2.68 B USD in 2026.

The market capitalization of Haemonetics changed from 2.68 B USD to 2.68 B USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Haemonetics since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Haemonetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Haemonetics

All Key Metrics — Haemonetics